Menu

Pharmaceuticals

Lilly to Adjust Organization and Leadership Structure to Better Align with Growth Opportunities

, , ,

Christi Shaw hired to lead Bio-Medicines; Conterno to assume additional geographic responsibilities, including Lilly USA leadership; Zulueta to lead International business INDIANAPOLIS, Jan. 5, 2017 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced a series of changes to its organization and leadership structure to better align them with the company’s growth opportunities. Explaining […]

GSK confirms closure of agreement to divest non-core assets to Aspen

, , ,

AFRICA – 03 January 2017 – GlaxoSmithKline today announced the closure of one of its series of agreements with Aspen Pharmacare Holdings Limited (JSE: APN) and certain of its subsidiaries (“Aspen”), which were the subject of announcements by both companies on 12 September 2016. GSK and Aspen have terminated their collaboration in Sub-Saharan Africa and […]

Merck Receives Complete Response Letter from the U.S. FDA for ZETIA® (ezetimibe) and VYTORIN® (ezetimibe and simvastatin)

, , , ,

February 15, 2016 – KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter regarding Merck’s Supplemental New Drug Applications for ZETIA® and VYTORIN® for the reduction of the risk of cardiovascular events (cardiovascular death, nonfatal […]

Lilly Diabetes Helps Inspiring Students with Type 1 Diabetes Attend College Through Scholarship Donation

, , , , ,

Company supports Diabetes Scholars Foundation Scholarship fund for fourth year in a row ROLLING MEADOWS, Ill. and INDIANAPOLIS, Feb. 11, 2016 /PRNewswire/ — Attending college is a major milestone for many young people, but for those with type 1 diabetes, the journey can be extra demanding. Not only do these students juggle class schedules, assignments […]

American Diabetes Association® Survey Shows Summer Camp Can Positively Impact Children’s Disease Management Skills, Confidence and Stress

, , , ,

Lilly Diabetes commits $93,000 to support Association “Camperships” INDIANAPOLIS and ALEXANDRIA, Va., Feb. 3, 2016 /PRNewswire/ — A three-year survey by the American Diabetes Association (Association) shows attending summer camp can do much more than lift the spirits of children with type 1 diabetes. Surveys conducted with caregivers before and after their child attended an […]

Lilly and Roche Diagnostics to Collaborate on Alzheimer’s Disease Adjunct Diagnostic Tool

, , , ,

INDIANAPOLIS, Jan. 27, 2016 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced an arrangement to partner with Roche Diagnostics on its ongoing development of a commercially scalable cerebrospinal fluid assay for amyloid-beta 1-42. Together with tau tangles, the presence of amyloid in the brain is a key marker of Alzheimer’s disease, a condition […]

World Health Organization to Review Merck’s Investigational Ebola Vaccine for Emergency Use Assessment and Listing

, , , ,

KENILWORTH, N.J. December 23, 2015 –(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the application for Emergency Use Assessment and Listing (EUAL) for the company’s investigational Ebola Zaire vaccine, V920 (rVSV∆G-ZEBOV-GP, live attenuated), has been accepted for review by the World Health Organization (WHO). According to the WHO, […]

Bayer and CRISPR Therapeutics AG join Forces to Discover, Develop and Commercialize Potential Cures for Serious Genetic Diseases

, , ,

The novel joint venture focuses on fundamental breakthrough treatments through first systemic application of promising CRISPR-Cas9 gene editing technology / Bayer is investing USD 335 million in a long-term alliance with CRISPR Therapeutics through new Bayer LifeScience Center unit / The joint venture will combine two leading knowledge areas: CRISPR-Cas9 from CRISPR Therapeutics as well […]

GSK completes divestment of rights to ofatumumab for auto-immune indications to Novartis

, , , ,

21 December 2015, London – GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the completion of its transaction to divest its rights to ofatumumab for auto-immune indications to Novartis Pharma AG (“Novartis Pharma”), a subsidiary of Novartis AG, following regulatory approval. The consideration payable by Novartis Pharma to GSK may reach up to $1,034 million and comprises a series […]

GSK’s global HIV business ViiV Healthcare to acquire Bristol-Myers Squibb’s R&D HIV assets

, , , , ,

Two transactions further strengthen HIV pipeline and outlook 18 December 2015, London – GlaxoSmithKline plc (LSE: GSK) today announced that its global HIV business, ViiV Healthcare, has reached two separate agreements with Bristol-Myers Squibb, to acquire its late-stage HIV R&D assets; and to acquire Bristol-Myers Squibb’s portfolio of preclinical and discovery stage HIV research assets. Under the […]

«‹ 7 8 9 10›»